PE's Diagnostic Start-Up
This article was originally published in Start Up
Executive Summary
Less than four months after securing a broad license from Roche Molecular Systems to use PCR for clinical diagnostics, PE Corp. has hired Roche Molecular's CEO, Kathy Ordonez. PE has tasked her to build a new division within PE that will draw on technology resident in PE's Applied Biosystems Group and Celera Genomics Group, to develop, seek approval for, and market reagent and software-based standardized molecular diagnostic tests that will run on ABI's instruments.